small molecule multitarget antiangiogenic drugs Search Results


anlotinib  (MultiTarget Pharmaceuticals)
90
MultiTarget Pharmaceuticals anlotinib
Baseline characteristics of the study population.
Anlotinib, supplied by MultiTarget Pharmaceuticals, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/anlotinib/product/MultiTarget Pharmaceuticals
Average 90 stars, based on 1 article reviews
anlotinib - by Bioz Stars, 2026-05
90/100 stars
  Buy from Supplier
medulloblastoma european multitarget metronomic anti-angiogenic trial  (MultiTarget Pharmaceuticals)
90
MultiTarget Pharmaceuticals medulloblastoma european multitarget metronomic anti-angiogenic trial
Baseline characteristics of the study population.
Medulloblastoma European Multitarget Metronomic Anti Angiogenic Trial, supplied by MultiTarget Pharmaceuticals, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/medulloblastoma european multitarget metronomic anti-angiogenic trial/product/MultiTarget Pharmaceuticals
Average 90 stars, based on 1 article reviews
medulloblastoma european multitarget metronomic anti-angiogenic trial - by Bioz Stars, 2026-05
90/100 stars
  Buy from Supplier
antiangiogenic tyrosine kinase inhibitors (tkis)  (MultiTarget Pharmaceuticals)
90
MultiTarget Pharmaceuticals antiangiogenic tyrosine kinase inhibitors (tkis)
Baseline characteristics of the study population.
Antiangiogenic Tyrosine Kinase Inhibitors (Tkis), supplied by MultiTarget Pharmaceuticals, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/antiangiogenic tyrosine kinase inhibitors (tkis)/product/MultiTarget Pharmaceuticals
Average 90 stars, based on 1 article reviews
antiangiogenic tyrosine kinase inhibitors (tkis) - by Bioz Stars, 2026-05
90/100 stars
  Buy from Supplier
multitarget antiangiogenic drug  (MultiTarget Pharmaceuticals)
90
MultiTarget Pharmaceuticals multitarget antiangiogenic drug
Baseline characteristics of the study population.
Multitarget Antiangiogenic Drug, supplied by MultiTarget Pharmaceuticals, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/multitarget antiangiogenic drug/product/MultiTarget Pharmaceuticals
Average 90 stars, based on 1 article reviews
multitarget antiangiogenic drug - by Bioz Stars, 2026-05
90/100 stars
  Buy from Supplier
antiangiogenic agents  (MultiTarget Pharmaceuticals)
90
MultiTarget Pharmaceuticals antiangiogenic agents
Baseline characteristics of the study population.
Antiangiogenic Agents, supplied by MultiTarget Pharmaceuticals, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/antiangiogenic agents/product/MultiTarget Pharmaceuticals
Average 90 stars, based on 1 article reviews
antiangiogenic agents - by Bioz Stars, 2026-05
90/100 stars
  Buy from Supplier
antiangiogenic multitarget kinase inhibitors  (MultiTarget Pharmaceuticals)
90
MultiTarget Pharmaceuticals antiangiogenic multitarget kinase inhibitors
Baseline characteristics of the study population.
Antiangiogenic Multitarget Kinase Inhibitors, supplied by MultiTarget Pharmaceuticals, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/antiangiogenic multitarget kinase inhibitors/product/MultiTarget Pharmaceuticals
Average 90 stars, based on 1 article reviews
antiangiogenic multitarget kinase inhibitors - by Bioz Stars, 2026-05
90/100 stars
  Buy from Supplier
multitarget anti-angiogenic drug  (MultiTarget Pharmaceuticals)
90
MultiTarget Pharmaceuticals multitarget anti-angiogenic drug
Baseline characteristics of the study population.
Multitarget Anti Angiogenic Drug, supplied by MultiTarget Pharmaceuticals, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/multitarget anti-angiogenic drug/product/MultiTarget Pharmaceuticals
Average 90 stars, based on 1 article reviews
multitarget anti-angiogenic drug - by Bioz Stars, 2026-05
90/100 stars
  Buy from Supplier
antiangiogenic metronomic combinatorial approach  (MultiTarget Pharmaceuticals)
90
MultiTarget Pharmaceuticals antiangiogenic metronomic combinatorial approach
Baseline characteristics of the study population.
Antiangiogenic Metronomic Combinatorial Approach, supplied by MultiTarget Pharmaceuticals, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/antiangiogenic metronomic combinatorial approach/product/MultiTarget Pharmaceuticals
Average 90 stars, based on 1 article reviews
antiangiogenic metronomic combinatorial approach - by Bioz Stars, 2026-05
90/100 stars
  Buy from Supplier
multitarget tkis  (MultiTarget Pharmaceuticals)
90
MultiTarget Pharmaceuticals multitarget tkis
Baseline characteristics of the study population.
Multitarget Tkis, supplied by MultiTarget Pharmaceuticals, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/multitarget tkis/product/MultiTarget Pharmaceuticals
Average 90 stars, based on 1 article reviews
multitarget tkis - by Bioz Stars, 2026-05
90/100 stars
  Buy from Supplier
multitargeted antiangiogenic agent sunitinib  (Pfizer Inc)
90
Pfizer Inc multitargeted antiangiogenic agent sunitinib
Baseline characteristics of the study population.
Multitargeted Antiangiogenic Agent Sunitinib, supplied by Pfizer Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/multitargeted antiangiogenic agent sunitinib/product/Pfizer Inc
Average 90 stars, based on 1 article reviews
multitargeted antiangiogenic agent sunitinib - by Bioz Stars, 2026-05
90/100 stars
  Buy from Supplier
serms  (MultiTarget Pharmaceuticals)
90
MultiTarget Pharmaceuticals serms
Baseline characteristics of the study population.
Serms, supplied by MultiTarget Pharmaceuticals, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/serms/product/MultiTarget Pharmaceuticals
Average 90 stars, based on 1 article reviews
serms - by Bioz Stars, 2026-05
90/100 stars
  Buy from Supplier
phytochemicals  (MultiTarget Pharmaceuticals)
90
MultiTarget Pharmaceuticals phytochemicals
Baseline characteristics of the study population.
Phytochemicals, supplied by MultiTarget Pharmaceuticals, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/phytochemicals/product/MultiTarget Pharmaceuticals
Average 90 stars, based on 1 article reviews
phytochemicals - by Bioz Stars, 2026-05
90/100 stars
  Buy from Supplier

Image Search Results


Baseline characteristics of the study population.

Journal: Cancer Medicine

Article Title: Immunotherapy combined with antiangiogenic therapy as third‐ or further‐line therapy for stage IV non‐small cell lung cancer patients with ECOG performance status 2: A retrospective study

doi: 10.1002/cam4.7349

Figure Lengend Snippet: Baseline characteristics of the study population.

Article Snippet: In this context, the ALTER0303 trial showed that third‐line treatment with anlotinib (a multitarget small‐molecule antiangiogenic drug) improved progression‐free survival (PFS) in NSCLC patients.

Techniques: Recombinant

Univariable and multivariable Cox regression analyses of factors associated with progression‐free survival.

Journal: Cancer Medicine

Article Title: Immunotherapy combined with antiangiogenic therapy as third‐ or further‐line therapy for stage IV non‐small cell lung cancer patients with ECOG performance status 2: A retrospective study

doi: 10.1002/cam4.7349

Figure Lengend Snippet: Univariable and multivariable Cox regression analyses of factors associated with progression‐free survival.

Article Snippet: In this context, the ALTER0303 trial showed that third‐line treatment with anlotinib (a multitarget small‐molecule antiangiogenic drug) improved progression‐free survival (PFS) in NSCLC patients.

Techniques:

Univariable and multivariable Cox regression analyses of factors associated with overall survival.

Journal: Cancer Medicine

Article Title: Immunotherapy combined with antiangiogenic therapy as third‐ or further‐line therapy for stage IV non‐small cell lung cancer patients with ECOG performance status 2: A retrospective study

doi: 10.1002/cam4.7349

Figure Lengend Snippet: Univariable and multivariable Cox regression analyses of factors associated with overall survival.

Article Snippet: In this context, the ALTER0303 trial showed that third‐line treatment with anlotinib (a multitarget small‐molecule antiangiogenic drug) improved progression‐free survival (PFS) in NSCLC patients.

Techniques: